Do hospital microbiology laboratories still need to distinguish Candida albicans from Candida dubliniensis?
作者信息
Lockhart Shawn R
出版信息
J Clin Microbiol. 2011 Dec;49(12):4415. doi: 10.1128/JCM.05923-11. Epub 2011 Oct 12.
Abstract
摘要
相似文献
1
Do hospital microbiology laboratories still need to distinguish Candida albicans from Candida dubliniensis?
J Clin Microbiol. 2011 Dec;49(12):4415. doi: 10.1128/JCM.05923-11. Epub 2011 Oct 12.
2
Can Multidrug-Resistant Candida auris Be Reliably Identified in Clinical Microbiology Laboratories?
J Clin Microbiol. 2017 Feb;55(2):638-640. doi: 10.1128/JCM.02202-16. Epub 2016 Nov 23.
3
Rapid Identification of Candida Species from Positive Blood Cultures by Use of the FilmArray Blood Culture Identification Panel.
J Clin Microbiol. 2018 Nov 27;56(12). doi: 10.1128/JCM.01387-18. Print 2018 Dec.
4
Identification of local clinical Candida isolates using CHROMagar Candida™ as a primary identification method for various Candida species.
Trop Biomed. 2011 Aug;28(2):269-74.
5
Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris.
J Clin Microbiol. 2017 Dec;55(12):3324-3327. doi: 10.1128/JCM.01355-17. Epub 2017 Sep 13.
6
Performance comparison of phenotypic and molecular methods for detection and differentiation of Candida albicans and Candida dubliniensis.
BMC Infect Dis. 2012 Sep 25;12:230. doi: 10.1186/1471-2334-12-230.
7
[Rapid identification of Candida dubliniensis using the Bichro-Dubli test].
Enferm Infecc Microbiol Clin. 2007 Nov;25(9):576-8. doi: 10.1157/13111184.
8
Methods of Candida dubliniensis identification and its occurrence in human clinical material.
Folia Microbiol (Praha). 2017 Sep;62(5):401-408. doi: 10.1007/s12223-017-0510-2. Epub 2017 May 17.
9
Hypertonic xylose agar medium: A novel medium for differentiation of from .
Indian J Med Microbiol. 2017 Oct-Dec;35(4):518-521. doi: 10.4103/ijmm.IJMM_17_216.
10
Identification of Candida dubliniensis in a diagnostic microbiology laboratory.
East Mediterr Health J. 2005 May;11(3):366-71.
引用本文的文献
1
Molecular identification and antifungal susceptibility profiles of Candida dubliniensis and Candida africana isolated from vulvovaginal candidiasis: A single-centre experience in Iran.
Mycoses. 2021 Jul;64(7):771-779. doi: 10.1111/myc.13280. Epub 2021 May 3.
2
Recent Taxonomic Developments with and Other Opportunistic Yeasts.
Curr Fungal Infect Rep. 2012 Sep;6(3):170-177. doi: 10.1007/s12281-012-0094-x.
3
Candida dubliniensis encrustation of an obstructing upper renal tract calculus.
BMJ Case Rep. 2013 Aug 23;2013:bcr2013009087. doi: 10.1136/bcr-2013-009087.
本文引用的文献
1
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
Drug Resist Updat. 2010 Dec;13(6):180-95. doi: 10.1016/j.drup.2010.09.002. Epub 2010 Nov 2.
2
National surveillance of fungemia in Denmark (2004 to 2009).
J Clin Microbiol. 2011 Jan;49(1):325-34. doi: 10.1128/JCM.01811-10. Epub 2010 Oct 27.
3
Utility of a Luminex-based assay for multiplexed, rapid species identification of Candida isolates from an ongoing candidemia surveillance.
Can J Microbiol. 2010 Apr;56(4):348-51. doi: 10.1139/w10-003.
4
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
J Clin Microbiol. 2010 Apr;48(4):1366-77. doi: 10.1128/JCM.02117-09. Epub 2010 Feb 17.
5
Phenotypic methods and commercial systems for the discrimination between C. albicans and C. dubliniensis.
Oral Dis. 2005 Nov;11(6):392-8. doi: 10.1111/j.1601-0825.2005.01135.x.
6
Azole susceptibility and resistance in Candida dubliniensis.
Biochem Soc Trans. 2005 Nov;33(Pt 5):1210-4. doi: 10.1042/BST20051210.
7
Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans.
FEMS Yeast Res. 2004 Jan;4(4-5):369-76. doi: 10.1016/S1567-1356(03)00240-X.
8
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
J Clin Microbiol. 2002 Sep;40(9):3135-9. doi: 10.1128/JCM.40.9.3135-3139.2002.
9
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
Antimicrob Agents Chemother. 1997 Mar;41(3):617-23. doi: 10.1128/AAC.41.3.617.
10
Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.
Microbiology (Reading). 1995 Jul;141 ( Pt 7):1507-21. doi: 10.1099/13500872-141-7-1507.
Zotero 插件